Financials

  • Market Capitalization 290.2152 M
  • Employee 80
  • Founded 1989
  • CEO N/A
  • Website www.amarincorp.com
  • Headquarter United Kingdom
  • FIGI BBG000BPYG99
  • Industry Arzneimittelhersteller – allgemein
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
-155.06
Preis-Umsatz-Verhältnis
27.11

Amarin Corporation plc - American Depositary Shares, each repre

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza.

Nachrichten